Citadel Advisors
AVTX icon

Citadel Advisors’s Avalo Therapeutics AVTX Stock Holding History

Citadel Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.89M Sell
193,735
-225,756
-54% -$3.53M ﹤0.01% 5337
2025
Q4 		$7.62M Sell
419,491
-62,178
-13% -$1.05M ﹤0.01% 3636
2025
Q3 		$6.12M Buy
+481,669
New +$4.14M ﹤0.01% 3997
2022
Q3 		– Sell
-31
Closed -$44K – 12586
2022
Q2 		$44K Buy
31
+21
+210% +$28.1K ﹤0.01% 12009
2022
Q1 		$22K Sell
10
-12
-55% -$30.1K ﹤0.01% 13216
2021
Q4 		$107K Buy
22
+11
+100% +$66K ﹤0.01% 12650
2021
Q3 		$68K Buy
11
+3
+38% +$24.3K ﹤0.01% 13175
2021
Q2 		$79K Buy
+8
New +$67K ﹤0.01% 13083
2020
Q4 		– Sell
-5
Closed -$32K – 10892
2020
Q3 		$32K Sell
5
-2
-29% -$15K ﹤0.01% 9741
2020
Q2 		$51K Sell
7
-4
-36% -$29K ﹤0.01% 9292
2020
Q1 		$81K Buy
+11
New +$116K ﹤0.01% 8769
2018
Q2 		– Sell
-7
Closed -$86K – 8798
2018
Q1 		$86K Sell
7
-2
-22% -$22.5K ﹤0.01% 7764
2017
Q4 		$84K Buy
+9
New +$38.8K ﹤0.01% 7487
2017
Q3 		– Sell
-6
Closed -$10K – 7509
2017
Q2 		$10K Buy
+6
New +$9.8K ﹤0.01% 7371
2017
Q1 		– Sell
-6
Closed -$16K – 7418
2016
Q4 		$16K Buy
+6
New +$54.7K ﹤0.01% 7119
2016
Q1 		– Sell
-2
Closed -$19K – 6758
2015
Q4 		$19K Buy
+2
New +$21.9K ﹤0.01% 7956

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Citadel Advisors's AVTX Position: Q1 2026 in Review

Citadel Advisors reduced its Avalo Therapeutics (AVTX) stake by 54% in Q1 2026, selling an estimated $3.53M and leaving 193,735 shares worth $2.89M. The position accounts for ﹤0.01% of the portfolio, ranked #5337.

Citadel Advisors first reported a position in AVTX in Q4 2015 and has held it in 16 quarters since. The position peaked at $7.62M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Citadel Advisors held 193,735 shares of Avalo Therapeutics worth $2.89M as of Q1 2026.
  • Citadel Advisors sold 225,756 Avalo Therapeutics shares in Q1 2026, an estimated $3.53M.
  • Avalo Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5337 holding.
  • Citadel Advisors first reported a position in Avalo Therapeutics in Q4 2015 and has held it in 16 quarters since.
  • Citadel Advisors's Avalo Therapeutics position peaked at $7.62M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.